Olivier Martinez

Director/Board Member at INNATE PHARMA

52 year

Health Technology

Finance

Consumer Services

Profile

Dr. Olivier Martinez is an Investment Director at BPIFrance Investissement SAS, a Chairman at SA Seridis and a Chairman & Chief Executive Officer at Société d'Amenagement des Territoires et d'Equipement.
He is on the Board of Directors at ABIONYX Pharma SA, Innate Pharma SA and Alizé Pharma SARL. Dr. Martinez was previously employed as an Investment Director by CDC Entreprises Valeurs Moyennes SAS, an Investment Director by Cdc Entreprises SAS, a Director-Investments & Member-Management Board by Bioam Gestion SA, a Partner by Bioam Gestion SA, a Chairman by Cytheris SA, a Member-Supervisory Board by Emergence Therapeutics AG, and a Member-Supervisory Board by Genticel SA. He also served on the board at Adocia SA, Poxel SA, Innate Pharma SA, FAB Pharma SAS, HalioDx SASU and Millendo Therapeutics SAS. He received his undergraduate degree from École Normale Supérieure and an MBA from the College des Ingenieurs.

Olivier Martinez active positions

Companies	Position	Start
ABIONYX PHARMA SA	Director/Board Member	2010-07-19
INNATE PHARMA	Director/Board Member	2021-06-29
Alizé Pharma SARL	Director/Board Member	-
Société d'Amenagement des Territoires & d'Equipement des Société d'Amenagement des Territoires & d'Equipement des Engineering & ConstructionIndustrial Services Provides civil engineering construction work services	Chief Executive Officer	-
SA Seridis SA Seridis Food RetailRetail Trade Operates supermarkets	Chairman	-
BPIFrance Investissement SAS BPIFrance Investissement SAS Investment ManagersFinance BPIfrance Investissement is an active manager focused on small, medium and intermdiate-sized businesses with high-growth potential. They favor sectors related to industry and technology and focus on investments in France. The firm invests either directly through dedicated investment funds or indirectly through private equity funds, partnerships and fund of funds managed by third parties. They invest across development stages, from start-ups to small LBO operations resulting from corporate succession issues. Their deal-sourcing process is both regional and national.	Private Equity Investor	2010-10-13

All active positions of Olivier Martinez

Former positions of Olivier Martinez

Companies	Position	End
ADOCIA	Director/Board Member	2022-11-30
INNATE PHARMA	Director/Board Member	2016-06-01
CDC Croissance SA CDC Croissance SA Investment ManagersFinance CDC Croissance develops an investment strategy for their clients based on each client's financial goals, time horizon and risk tolerance.	Chief Investment Officer	2012-12-31
░░░ ░░░░░░░░░░░ ░░░	░░░░░░░░░ ░░░░░░░░░░░░░░░░░	░░░░░░░░░░
░░░░░ ░░░░░░░ ░░	░░░░░░░░ ░░ ░░░░░░░░░░░	░░░░░░░░░░

See the detail of Olivier Martinez's experience

Training of Olivier Martinez

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Olivier Martinez's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	20
Poxel SA Poxel SA Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biopharmaceutical company, focuses on the development of novel treatments for serious chronic diseases	Health Technology
Bioam Gestion SA Bioam Gestion SA Investment ManagersFinance BG is a venture capital investment management firm specialized in early-stage financing of biotechnology companies. They target start-ups with high growth potential, spawned by French and European public or private sector life science research, and more particularly applications in the healthcare, environment, agricultural and food industries. Within the healthcare sector BG focuses on biopharmaceuticals, medical instrumentation and diagnosis systems. BG provides seed capital, generally investing in the first institutional round of financing, and later participating in subsequent rounds. The firm usually joins forces with French or foreign co-investors. BG invests in France and in Europe. The firm sources deals through their extensive network in the French academic community and in the biopharmaceutical industry. BG is an active investor who sits on the board and provides strategic advisory as well as development assistance to their portfolio companies.	Finance
Innate Pharma SA Innate Pharma SA Pharmaceuticals: MajorHealth Technology Develops therapeutic antibodies that harness the immune system to improve cancer treatment and clinical outcomes	Health Technology
Cytheris SA Cytheris SA Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for immune modulation	Health Technology
ABIONYX Pharma SA ABIONYX Pharma SA Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes novel HDL therapies for the treatment of cardiovascular and metabolic diseases	Health Technology
Université de Paris XI Paris Sud Université de Paris XI Paris Sud Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
École Normale Supérieure École Normale Supérieure Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
BPIFrance Investissement SAS BPIFrance Investissement SAS Investment ManagersFinance BPIfrance Investissement is an active manager focused on small, medium and intermdiate-sized businesses with high-growth potential. They favor sectors related to industry and technology and focus on investments in France. The firm invests either directly through dedicated investment funds or indirectly through private equity funds, partnerships and fund of funds managed by third parties. They invest across development stages, from start-ups to small LBO operations resulting from corporate succession issues. Their deal-sourcing process is both regional and national.	Finance
CDC Croissance SA CDC Croissance SA Investment ManagersFinance CDC Croissance develops an investment strategy for their clients based on each client's financial goals, time horizon and risk tolerance.	Finance
Genticel SA Genticel SA BiotechnologyHealth Technology Develops vaccines for patients infected with human papillomavirus	Health Technology
Adocia SA Adocia SA Pharmaceuticals: MajorHealth Technology Manufactures novel therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases	Health Technology
Millendo Therapeutics SAS Millendo Therapeutics SAS Medical SpecialtiesHealth Technology Provides pharmaceutical research services	Health Technology
FAB Pharma SAS FAB Pharma SAS Miscellaneous Commercial ServicesCommercial Services Develops drugs for the treatments of bacterial infections	Commercial Services
SA Seridis SA Seridis Food RetailRetail Trade Operates supermarkets	Retail Trade
College des Ingenieurs College des Ingenieurs Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
HalioDx SASU HalioDx SASU BiotechnologyHealth Technology Engages in research and development of immuno-oncology diagnostics	Health Technology
Cdc Entreprises SAS Cdc Entreprises SAS Investment ManagersFinance Operates as a private equity fund	Finance
Emergence Therapeutics AG Emergence Therapeutics AG Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company which develops novel antibody drugs	Health Technology
Alizé Pharma SARL
Société d'Amenagement des Territoires & d'Equipement des Société d'Amenagement des Territoires & d'Equipement des Engineering & ConstructionIndustrial Services Provides civil engineering construction work services	Industrial Services